---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000082"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:11:34.342607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioMarin to cut ~170 jobs, book $15-20M charge from R&D program exits

## Summary
- Strategic portfolio assessment led to discontinuation of certain R&D programs.
- Workforce reduction of approximately 170 employees; majority notified May 14, 2024.
- Estimated $15-20M pre-tax charges in Q2 2024 for severance and termination benefits.
- Workforce reductions expected to be substantially completed by end of July 2024.

## SEC filing metadata
- accession: 0001048477-24-000082
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000082/0001048477-24-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000082/bmrn-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000082
- JSON: https://secwatch.observer/filing/0001048477-24-000082.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000082.txt

## Source-grounded claims
- claim_id: 388f88e6e7602560b98c183e494f4abeb941de65
  claim: BIOMARIN PHARMACEUTICAL INC announced a restructuring with charges of approximately $15 - $20 million affecting research and development programs (approximately 170 employees).
  evidence_excerpt: In connection with the discontinuation of certain research and development programs, on May 9, 2024, the Company committed to a plan to reduce its global workforce by approximately 170 employees. The Company estimates that it will incur aggregate pre-tax charges of approximately $15 - $20 million during the second quarter of 2024, representing one-time cash expenditures for severance and other employee termination benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000082/0001048477-24-000082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.